| ²é¿´: 493 | »Ø¸´: 1 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
fyw921ͳæ (СÓÐÃûÆø)
|
[ÇóÖú]
fuse to Óëeither andµÄ·Òë
|
|
|
1£¬The tyrosinase-related protein peptides TRP2: 180¨C188 (SVYDFFVWL) and TRP2: 181¨C188 (VYDFFVWL), as well as the modified p53 peptide (p53: 232¨C240; KYICNSSCM) fused to PADRE (AKXVAAWTLKAAA, where X is cyclohexylalanine) were purchased from Dalton Chemical Laboratories Inc.ÇëÎÊÕâ¾ä»°ÖÐTRP2¼°p53ÓëPADREÊÇÎïÀí»ìºÏ»¹ÊÇ»¯Ñ§Á¬½Óµ½Ò»Æð£¿ 2£¬All formulations of the vaccines contained either PADRE (AKXVAAWTLKAAA-OH; 25 ¦Ìg/dose) and CpG ODN 1826 (5'-TCCATGACGTTCCTGACGTT-3'; Coley Pharmaceutical, Wellesley, MA; 50 ¦Ìg/dose). ÇëÎÊÕâ¾ä»°ÖÐÒßÃçÊÇÖ»º¬ÓÐPADRE»òÕßCPGÖеÄÒ»ÖÖ»¹ÊÇÁ½Õß¶¼º¬ÓУ¿ |
» ²ÂÄãϲ»¶
085600²ÄÁÏÓ뻯¹¤301·ÖÇóµ÷¼ÁԺУ
ÒѾÓÐ5È˻ظ´
081700£¬311£¬Çóµ÷¼Á
ÒѾÓÐ15È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤085600 310·ÖÇóµ÷¼Á
ÒѾÓÐ18È˻ظ´
²ÄÁÏÓ뻯¹¤371Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
336²ÄÁÏÓ뻯¹¤085600Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
²ÄÁÏ334Çóµ÷¼Á
ÒѾÓÐ18È˻ظ´
331Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
332Çóµ÷¼Á
ÒѾÓÐ17È˻ظ´
Ò»Ö¾Ô¸ÄϾ©º½¿Õº½Ìì´óѧ ²ÄÁÏÓ뻯¹¤329·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
²ÄÁÏר˶322
ÒѾÓÐ7È˻ظ´
ssssllllnnnn
ÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)
Translator and Proofreader
- ·ÒëEPI: 1690
- Ó¦Öú: 452 (˶ʿ)
- ½ð±Ò: 31580.9
- ºì»¨: 100
- Ìû×Ó: 7681
- ÔÚÏß: 19966.6Сʱ
- ³æºÅ: 3328089
- ×¢²á: 2014-07-17
- רҵ: Ö×Áö·¢Éú
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
ÕæÇ¿±ØÊ¤: ½ð±Ò+1, лл 2014-08-06 08:19:04
fyw921: ½ð±Ò+10, ·ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸ 2014-08-06 11:09:47
ÕæÇ¿±ØÊ¤: ½ð±Ò+1, лл 2014-08-06 08:19:04
fyw921: ½ð±Ò+10, ·ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸ 2014-08-06 11:09:47
|
1¡¢²»ÊÇ»ìºÏ£¬ÊÇÔںϳÉʱ·Ö±ð½«TRP2: 180¨C188 (SVYDFFVWL)¡¢TRP2: 181¨C188 (VYDFFVWL), ºÍp53ëĶÎ(p53: 232¨C240; KYICNSSCM)ÓëPADRE(AKXVAAWTLKAAA)ºÏ³É³ÉÒ»ÌõеÄëĶΡ£¾ÙÀý˵£º TRP2: 180¨C188 (SVYDFFVWL)ºÍPADRE(AKXVAAWTLKAAA)ÈںϺóÐγÉÐÂëĶÎTRP2: 180¨C188£PADRE£º SVYDFFVWLAKXVAAWTLKAAAµÈ¡£ 2¡¢eitherÊÇÖ¸°üÀ¨ËùºÏ³ÉµÄÐÂëĶÎÖеÄÒ»ÖÖ£¬andÊǺÍCpG ODN¡£¾ÍÊÇ˵ÓÐÈýÖÖformulations£¬Ã¿Ò»ÖÖ¶¼º¬ÓÐCpG£¬Áí¼ÓкͳɵÄÈýÖÖPADREëĶÎÖ®Ò»¡£ Ï£ÍûÎÒÒѾΪÄã½âÊÍÇå³þÁË¡£ |
2Â¥2014-08-05 21:26:24














»Ø¸´´ËÂ¥